Abstract
Eleven patients with chronic uveitis treated with Cyclosporine were immunized with keyhole limpet hemocyanin (KLH) and tetanus toxoid. Delayed cutaneous hypersensitivity responses, lymphocyte blastogenic responses, and antibody production were compared with those of similarly immunized control individuals. A significant decrease in delayed cutaneous hypersensitivity (P<0.001 for KLH andP<0.01 for tetanus toxoid) was observed. No significant differences in blastogenic or antibody responses were noted. These findings demonstrate that the majority of the Cyclosporine-treated patients had intact T cell-dependent antigen responses as measured by both proliferative response and antibody production to primary and secondary antigenic challenges but that other immune functions such as delayed cutaneous hypersensitivity are affected by therapeutic doses of systemic Cyclosporine.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
The Canadian Multicentre Transplant Study Group: A randomized clinical trial of cyclosporine in cadaveric renal transplantation. N Engl J Med 309:809–815, 1983
Lafferty KJ, Borel JF, Hodgkin P: Cyclosporine-A (CsA): Models for the mechanism of action. Transplant Proc 15(4) Suppl 1:2242–2247, 1983
Bunjes D, Hardt C, Rollinghoff M, Wagner H: Cyclosporine A mediates immunosuppression of primary cytotoxic T cell responses by impairing the release of interleukin 1 and interleukin 2. Eur J Immunol 11:657–661, 1981
Dos Reis GA, Shevach EM: Effect of Cyclosporin A on T cell function in vitro: The mechanism of suppression of T cell proliferation depends on the nature of the T cell stimulus as well as the differentiation state of the responding T cell. J Immunol 129:2360–2367, 1982
Kronke M, Leonard WJ, Pepper JM, Wong-Stool F, Gallo RC, Waldman TA, Greene WC: Cyclosporin A inhibits and cell growth factor gene expression. Clin Res 32:351A, 1984
Muraguchi A, Butler FL, Kehrl JH, Falkoff RJM, Fauci AS: Selected suppression of an early step in human B cell activation by Cyclosporin A. J Exp Med 158:690–702, 1983
Kunkel A, Galus GGB: Selective effects of Cyclosporin A on functional B cell subsets in the mouse. J Immunol 125:2526–2531, 1980
Mochizuki M, Nussenblatt RB, Kuwabara T, Gery I: Effects of cyclosporine on the eferent limb of the immune response. Transplant Proc 15(4) Suppl 1:2364–2366, 1983
Nussenblatt RB, Rodrigues MM, Wacker WB, Cevario SJ, Salinas-Carmona MC, Gery I: Cyclosporin A: Inhibition of experimental autoimmune uveitis in Lewis rats. J Clin Invest 67:1228–1231, 1981
Chan CC, Palestine AG, Nussenblatt RB: Cyclosporine induced alterations of humoral response in experimental autoimmune uveitis. Invest Ophthal 25:867–870, 1984
Ho M, Wajszczuk CP, Hardy A, Dummer JS, Starzl TE, Hakala TR, Bahnson HT: Infections in kidney, heart, and liver transplant recipients on Cyclosporine. Transplant Proc 15(4) Suppl 1:2768–2772, 1983
Hardy AM, Wajszczuk CP, Hakala TR, Rosenthal JT, Starzl TE, Ho M: Infection in renal transplant recipients on Cyclosporine: Pneumocystis pneumonia. Transplant Proc 15(4) Suppl 1:2773–2778, 1983
Dummer JS, Bahnson HT, Griffith BP, Hardesty RL, Thompson ME, Ho M: Infections in patients on Cyclosporine and Prednisone following cardiac transplantation. Transplant Proc 15(4) Suppl 1:2779–2781, 1983
Nussenblatt RB, Palestine AG, Rook AH, Scher I, Wacker WB, Gery I: Treatment of intraocular inflammatory disease with Cyclosporin A. Lancet 1:235–238, 1983
Nussenblatt RB, Palestine AG, Chan CC: Cyclosporin A therapy in the treatment of intraocular inflammatory disease resistant to systemic corticosteroids and cytotoxic agents. Am J Ophthal 96:275–282, 1983
Palestine AG, Nusenblatt RB, Chan CC: Side effects of Cyclosporine in nontransplant patients. Am J Med (in press)
Vokman DJ, Lane HC, Fauci AS: Antigen-induced in vitro antibody production in humans: A model for B cell activation and immunoregulation. Proc Natl Acad Sci 78:2528–2531, 1981
Lane HC, Volkman DJ, Whalen G, Fauci AS: In vitro antigen-induced, antigen-specific antibody production in man. J Exp Med 154:1043–1057, 1981
Volkman DJ, Allyn SP, Fauci AS: Antigen-induced in vitro antibody production in humans: Tetanus toxoid specific antibody synthesis. J Immunol 129:1:107–112, 1982
Harley JB, Fauci AS: Cyclosporine modulates the human in vitro T-dependent antigen-induced synthesis of specific antibody. Transplant Proc 15(4) Suppl 1:2315–2320, 1983
Thomson AW, Moon DK, Nelson DS: Suppression of delayed-type hypersensitivity reactions and lymphokine production by cyclosporin A in the mouse. Clin Exp Immunol 52:599–606, 1983
Rumjanek VM, Smith LA, Morely J: Cyclosporin A—a prerecruitment action in the cutaneous response?: Immunol Lett 6:69–72, 1983
Allison MC, Pounder RE: Cyclosporin for Crohn's disease. Lancet 1:902, 1984
Rebuck AS, Stiller CR, Braude AC, Laupacis A, Cohen RD, Chapman KR: Cyclosporin for pulmonary sarcoidosis. Lancet 1:1174, 1984
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Palestine, A.G., Roberge, F., Charous, B.L. et al. The effect of cyclosporine on immunization with tetanus and keyhole limpet hemocyanin (KLH) in humans. J Clin Immunol 5, 115–121 (1985). https://doi.org/10.1007/BF00915009
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00915009